SWM
ESPR

SeaCrest Wealth Management’s Esperion Therapeutics ESPR Stock Holding History

SeaCrest Wealth Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50
Closed -$2K – 912
2019
Q1 		$2K Hold
50
– – ﹤0.01% 1912
2018
Q4 		$2K Hold
50
– – ﹤0.01% 1902
2018
Q3 		$2K Sell
50
-92
-65% -$4.22K ﹤0.01% 2053
2018
Q2 		$6K Hold
142
– – ﹤0.01% 1762
2018
Q1 		$10K Buy
142
+50
+54% +$3.67K ﹤0.01% 1575
2017
Q4 		$6K Buy
+92
New +$4.95K ﹤0.01% 1751

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

SeaCrest Wealth Management's ESPR Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Esperion Therapeutics (ESPR) in Q2 2019, closing a stake of 50 shares — an estimated $2K sold.

SeaCrest Wealth Management first reported a position in ESPR in Q4 2017 and held it in 6 quarters. The position peaked at $10K in Q1 2018. 167 funds tracked by Wall St. Rank hold ESPR as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining Esperion Therapeutics position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 50 Esperion Therapeutics shares in Q2 2019, an estimated $2K.
  • SeaCrest Wealth Management first reported a position in Esperion Therapeutics in Q4 2017 and held it in 6 quarters.
  • SeaCrest Wealth Management's Esperion Therapeutics position peaked at $10K in Q1 2018.
  • 167 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.